Posted: DEC 12, 2007

CSMG Technologies Announces Top Ranked Wall Street Healthcare Analyst and Portfolio Manager Steven P. Delco Joins CSMG and Live Tissue Connect Team

Corpus Christi, TX, December 12, 2007 -- CSMG Technologies, Inc., (OTCBB: CTUM - News) President and CEO Donald S. Robbins today announced that a former top ranked Wall Street healthcare analyst and portfolio manager, Steven P. Delco of DELCO ADVISORS, LLC, (www.delcoadvisors.com), is joining the CSMG and subsidiary, Live Tissue Connect ("LTC"), team as a consultant.

"We are very pleased to have Steven Delco assist our company along with other high quality professionals who have already joined us as consultants. Steven has a stellar reputation and excellent contacts, world-wide, within the medical industry and with institutional investors. His primary focus will be to represent LTC to the European investment community,” said Mr. Robbins.

Mr. Delco brings over 25 years of healthcare strategic marketing, financial and Wall Street experience to LTC. Delco will assist in raising the awareness of international institutional investors to LTC’s advanced development in tissue bonding / welding technology.

Delco was principal portfolio manager in Health at Weiss Peck & Greer/ROBECO. He was also vice president and the senior biotech analyst at Natexis Bleichroeder where he led their biotech team. Prior to NB, Steven created and managed The Fortis Group healthcare research team as the senior analyst and managing director with groups reporting to him in Amsterdam, Paris and New York. He started his Wall Street career at Miller Tabak + Co. LLC after founding one of the first biotech investment newsletters online that gained him recognition on Wall Street. At MT, he built and headed the biotech research team.

In 1999, The Carson Group ranked Mr. Delco as the number one biotech analyst for his stock picking performance that achieved an annual return of 294%. Prior to Wall Street, Delco founded a prominent biotech instrumentation market research firm in 1982 in which he advised and provided market research to many life science and healthcare device and instrument companies. He has gained international recognition and his recommendations have been reported in the Wall Street Journal, Bloomberg Online and TV, as well as Reuters and many other US and international publications. In addition, Steven has had teaching and research appointments at Sloan-Kettering Institute for Cancer Research, University of Minnesota, and City University of New York.

On December 3, 2007, CSMG announced its subsidiary, LTC, received CE Mark certification for its new VAD.400 RF Generator. CSMG regards the CE Mark as an important milestone, allowing the generator to be sold in Europe. This is considered a major step toward launching the entire VAD-400 handpiece and generator system into the European markets. Presently CSMG and LTC are evaluating multiple distribution options, both in the U.S. and internationally.

About Live Tissue Connect

LTC's surgical tissue bonding / welding device is a patented platform technology that bonds and reconnects human soft tissue through fusion, in contrast with conventional wound closing devices such as sutures, staples, sealant, or glues. LTC currently holds a total of approximately 40 patents in the U.S., Australia, Canada, European Union, Ukraine and other countries.

For further information on CSMG Technologies and its various subsidiaries, please visit our website at www.csmgtechinternational.com.

Sign up to receive CSMG Technologies automated email press releases and other notifications: Please go to www.csmgtechinternational.com/contact_information.html and fill-in information.

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.

CONTACT:

CSMG Technologies, Inc.
Donald S. Robbins, President and CEO
361-887-7546
or
K. Bruce Jones, 770-955-0409
or
ROI Group Associates, Inc.
Michael Dodge, 212-495-0744
mdodge@roiny.com